Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
ICS/LABA — Asthma / COPD

Beclometasone / Formoterol

Brand names: Fostair 100/6, Fostair 200/6, Luforbec

Used in: Asthma

This is a fixed-dose inhaler combining the inhaled corticosteroid beclometasone with the long-acting beta-2 agonist formoterol, used as maintenance (and in some products maintenance-and-reliever) therapy for asthma and COPD.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Beclometasone reduces airway inflammation through glucocorticoid receptor activation, while formoterol is a rapid-onset long-acting beta-2 agonist that relaxes bronchial smooth muscle.

Prescribing in practice

  • Most important: a long-acting beta-2 agonist must never be used without the inhaled corticosteroid in asthma, so this fixed combination should not be co-prescribed with a separate LABA and adherence to the steroid component is essential.
  • Confirm the patient can use the specific device correctly, as extra-fine particle formulations are not interchangeable dose-for-dose with other beclometasone products.
  • Review inhaler technique and exacerbation frequency, and step therapy up or down according to control.

Monitoring

Monitor asthma or COPD control, inhaler technique, growth in children on long-term inhaled corticosteroid, and for candidiasis.

Counselling the patient

  • Rinse the mouth after inhaling to reduce oral thrush and hoarseness.
  • Use it regularly as prescribed even when feeling well, and carry a separate reliever unless told this inhaler is your reliever too.

Evidence & guidelines

ICS/LABA combination therapy is established in NICE, GINA, and GOLD guidance for persistent asthma and symptomatic COPD.

Reference: GINA 2024; COSMOS Trial; BTS/SIGN Asthma Guidelines 2019; SPC Fostair; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways